Bajaj Healthcare launches antiviral drug ‘Favijaj’
The company has received approval from India's drug regulator, to manufacture and market ‘Favijaj’
Bajaj Healthcare has launched ‘Favijaj’ (Favipiravir) an antiviral drug used for treating patients suffering from influenza virus and has proved to be effective over COVID patients. The company has received approval from India's drug regulator, to manufacture and market ‘Favijaj’ the oral Favipiravir approved medication in India for the treatment of COVID-19 from May 04, 2021.
‘Favijaj’tablets comprising Favipiravir in different dosage forms is used for the treatment of mild to moderate Covid-19 disease. Favipiravir is an antiviral drug, which has shown potent in vitro activity against severe acute respiratory syndrome of coronavirus.
Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.